BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 16409425)

  • 1. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).
    Fechner G; Siener R; Reimann M; Kobalz L; Albers P;
    Int J Clin Pract; 2006 Jan; 60(1):27-31. PubMed ID: 16409425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
    Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A
    Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
    Pectasides D; Glotsos J; Bountouroglou N; Kouloubinis A; Mitakidis N; Karvounis N; Ziras N; Athanassiou A
    Ann Oncol; 2002 Feb; 13(2):243-50. PubMed ID: 11886001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.
    Li J; Juliar B; Yiannoutsos C; Ansari R; Fox E; Fisch MJ; Einhorn LH; Sweeney CJ
    J Clin Oncol; 2005 Feb; 23(6):1185-91. PubMed ID: 15718315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
    Milowsky MI; Nanus DM; Maluf FC; Mironov S; Shi W; Iasonos A; Riches J; Regazzi A; Bajorin DF
    J Clin Oncol; 2009 Sep; 27(25):4062-7. PubMed ID: 19636012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.
    Lorusso V; Crucitta E; Silvestris N; Rosati G; Manzione L; De Lena M; Palmeri S; Gebbia V; Mancarella S; Sobrero A; Pezzella G; Comella P; Mangiameli A; Muci D;
    Oncol Rep; 2005 Feb; 13(2):283-7. PubMed ID: 15643512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].
    Albers P; Park SI; Niegisch G; Fechner G; Steiner U; Lehmann J; Heimbach D; Heidenreich A; Fimmers R; Siener R;
    Ann Oncol; 2011 Feb; 22(2):288-94. PubMed ID: 20682548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.
    Meluch AA; Greco FA; Burris HA; O'Rourke T; Ortega G; Steis RG; Morrissey LH; Johnson V; Hainsworth JD
    J Clin Oncol; 2001 Jun; 19(12):3018-24. PubMed ID: 11408496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
    Ecke TH; Bartel P; Koch S; Ruttloff J; Theissig F
    Oncol Rep; 2006 Dec; 16(6):1381-8. PubMed ID: 17089065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
    Halim A; Abotouk N
    Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
    Kanai K; Kikuchi E; Ohigashi T; Miyajima A; Nakagawa K; Nakashima J; Oya M
    Int J Clin Oncol; 2008 Dec; 13(6):510-4. PubMed ID: 19093178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
    Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
    Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Batiste-Alentorn E; Sáenz A; López-Brea M; Font A; Nogué M; Bastús R; Climent MA; de la Cruz JJ; Albanell J; Banús JM; Gallardo E; Diaz-Rubio E; Cortés-Funes H; Baselga J
    J Clin Oncol; 2000 Sep; 18(18):3247-55. PubMed ID: 10986057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer.
    Isokangas OP; Knuuttila A; Halme M; Mäntylä M; Lindström I; Nikkanen V; Viren M; Joensuu H; Mattson K
    Ann Oncol; 1999 Sep; 10(9):1059-63. PubMed ID: 10572603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.
    Adamo V; Magno C; Spitaleri G; Garipoli C; Maisano C; Alafaci E; Adamo B; Rossello R; Scandurra G; Scimone A
    Oncology; 2005; 69(5):391-8. PubMed ID: 16319510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
    Martoni A; Marino A; Sperandi F; Giaquinta S; Di Fabio F; Melotti B; Guaraldi M; Palomba G; Preti P; Petralia A; Artioli F; Picece V; Farris A; Mantovani L
    Eur J Cancer; 2005 Jan; 41(1):81-92. PubMed ID: 15617993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium.
    Ecke TH; Gerullis H; Bartel P; Koch S; Ruttloff J
    Minerva Urol Nefrol; 2009 Mar; 61(1):1-8. PubMed ID: 19417721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.
    Hussain SA; Stocken DD; Riley P; Palmer DH; Peake DR; Geh JI; Spooner D; James ND
    Br J Cancer; 2004 Aug; 91(5):844-9. PubMed ID: 15292922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.